Site search
2831 results for '' found
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
/
Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)
Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)
/
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Re
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Re
/
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)
/
Avatrombopag in Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy - Ava NEXT– a Bayesian Optimal Phase II study (ACTRN12619001043123)
Avatrombopag in Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy - Ava NEXT– a Bayesian Optimal Phase II study (ACTRN12619001043123)
/
Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – Ava FIRST- a Bayesian Optimal Phase II study (ACTRN12619001042134)
Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – Ava FIRST- a Bayesian Optimal Phase II study (ACTRN12619001042134)
/
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease (NCT06430801
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease (NCT06430801
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis (NCT06052059)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis (NCT06052059)
/
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (NCT05951049)
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (NCT05951049)
/